Qlaris Bio, Inc.

• 30/04/2024
• Series B
• $24,000,000

At Qlaris, our lead program is QLS-111, a novel topical ocular therapy that lowers intraocular pressure with a unique mechanism of action. QLS-111 is distinct from currently available therapies by selectively targeting episcleral venous pressure (EVP) and improving outflow distal to the trabecular meshwork. This novel mechanism may enable the improved treatment of diseases where EVP has limited therapy or has itself been pathologic, such as Normal Tension Glaucoma, Primary Open Angle Glaucoma, glaucoma associated with Sturge-Weber Syndrome, and also in combination with Minimally-Invasive Glaucoma Surgery (MIGS) devices.

---

---